Since 2000, there's been nothing by way of $$$ desserts for stockholders. Only, Merial, USA govt. & also
GNVC employees, hierarchy; indeed, NVS nowadays, who reign as beneficiaries!
We even did not have to wait until tomorrow!!!
20,000 options/shares gift to the new man........
Only question is why the execution price was not set at $6.
He will be able to be in the money at $2.97.............
How low will this BOD and Doug Swirsky go?
I have per-paid for this grim American Capitalism show.......might as well watch it till the bitter end.
Yes....I am very bitter......and you should be too...............
This is getting worse than before.
Pretty soon the BOD will exceed the FT employees.
Very sad indeed.
Yesterday- we have a useless PR with no cash, no product and no future.
Today- we get one more mouth to feed at the BOD.
What will tomorrow bring?- I do wonder........in a numb way.................
That is your problem bud. I have been long for longer than I should have. You better wake up.
not sure what you mean by 'land of the free' and my owners having the fed. you're sounding a little short these days max. rather than than intentionally misinterpreting company news on this board, save the aggravation, close your short position, and try to find an investment that makes you happy.
That is the key that everyone needs to understand- the human is only the carrier, the target is the mosquito. As such no human who is vaccinated with this vaccine will be able to achieve a protection level for themselves. If you still have any doubts e-mail Doug Brough and see what he says. Feel FREE to dream on.
Zoos7- my guess is that you live in the LAND of the "FREE".
As such please feel free to believe whatever you want.
My only hope is that you have enough money to support your believes long-term.
Your owners for example have the FED, so they seem to be set for a while..............
from the news release: "The focus (involves) . . . triggering the production of antibodies that are taken up by a mosquito when it bites a VACCINATED individual. "
i read that to mean that the human vaccines they are attempting to develop with gnvc's gorilla adenovector technology--which has been show to provoke a strong response from the human immune system--will protect those vaccinated as well as those downstream individuals who are subsequently bitten by a mosquito who previously bit a vaccinated person; thereby knocking out the antigen in the person and the carrier.
in terms of the financial provisions, no details are referenced. it is not identified as a grant, which would be involved in the type of prior grant-based projects you seem to reference. rather, it would seem to be the type of contract we've seen the company recently sign: "greater participation" in any future products in exchange for providing the technology needed. as this does not appear to be a grant, i would assume the govt will purchase the vectors; or, in the alternative, give gnvc "greater participation" in any future proceeds from any vaccines developed--with the company acting as both partner and venture capitalist-and with the govt funding and developing the vaccine.
important takeaways imo: govt chose our gorilla vectors rather than any competitors lesser monkey vectors. remember, in therapies such as hearing loss, a strong immune response is not necessarily involved or desired. but in vaccines, a strong immune response is required. as we have both types of vectors, our technology is amenable to both types of therapies. and the fact that the govt chose our gorilla vectors over the competitors lesser monkey vectors, suggests that they expect a greater immune response from our vectors than theirs. second, the agreement seems to suggest that the company is desirous of these arrangements which do not add significant cost, but do offer substantial upside participation.
Doesn't the human have to received a vaccine, so that when that human is bitten by a mosquito, the mosquito receives the antibodies which renders plasmodium falciparum useless/dead?
Sentiment: Strong Buy
Hi Gary: I do have to respectfully disagree with you on this one!!!
Please do your homework and you will see that this particular program has nothing to do with a human vaccine. The human will be only the carrier......while the mosquitos are the target.
One more time:
No CASH contribution.
No product in sight.
No private Pharma.
In other words the GenVec of old.........the one the nearly went BK.
Here is my bottom line: "SHOW ME THE MONEY".
All the best on your therapy.........looking forward to chat with you when you get back on-line.
This is a relationship that could result in vaccines for humans. I believe it may utilize the efforts of many companies, but in the end if a vaccine were approved with technology that came from GNVC, they would most certainly be entitled to part of the revenue stream. As for developmental costs, if the NIH sees something they want further developed, they can pay for it.
1. It is not a human vaccine. It is a transmission vaccine to effect the mosquitos. As such it has a way lower bar to pass.
2. No cash from this deal. Not even a penny. Another Gov DOD type of deal.
This is not a good sign as we are going back to what the "OLD" GenVec used to be- a bunch of useless mostly gov funded press releases.
Would not be surprised if we end the day lower.
If Doug thinks this non-sense will carry us forward he is WRONG.
The only thing that is happing is him and the rest of the crew are making their paychecks- for now.
Very lame......I am extremely unhappy!!!
There's a news release this morning about a new malaria collaboration. Here is part. The whole thing is here on Yahoo.
GAITHERSBURG, Md., April 21, 2015 /PRNewswire/ -- GenVec, Inc. (GNVC) today announced that it has signed a research collaboration agreement with the Laboratory of Malaria Immunology and Vaccinology (LMIV) of the National Institute of Allergy and Infectious Diseases, National Institutes of Health.
The research collaboration will utilize GenVec's proprietary gorilla adenovirus vectors to deliver a number of novel antigens discovered at the LMIV in order to create and test a variety of malaria vaccine candidates. GenVec will construct vaccine candidates at its laboratories and hand them off to LMIV's Vaccine Development Unit, which is headed by Patrick E. Duffy, M.D., for preclinical testing.